Drugs / VTX2735
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06836232 | Jan 2025 → Oct 2027 expected | pericarditis | Zomagen Biosciences Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05812781 | Mar 2023 → Mar 2024 | cryopyrin-associated periodic syndrome | Zomagen Biosciences Ltd. | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VTX2735 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06836232 ↗ |